{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:34:36Z","timestamp":1790253276735,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jaad.2019.08.089","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T01:53:53Z","timestamp":1570586033000},"page":"1061-1082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Hidradenitis suppurativa"],"prefix":"10.1016","volume":"82","author":[{"given":"Samantha R.","family":"Goldburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Payette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2019.08.089_bib1","first-page":"CD010081","article-title":"Interventions for hidradenitis suppurativa","volume":"10","author":"Ingram","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2019.08.089_bib2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/bjd.13866","article-title":"Management of hidradenitis suppurativa: a U.K. survey of current practice","volume":"173","author":"Ingram","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/0019-5154.190105","article-title":"Anti-inflammatory and immunomodulatory effects of antibiotics and their use in dermatology","volume":"61","author":"Pradhan","year":"2016","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000228337","article-title":"The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa","volume":"219","author":"van der Zee","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2019.08.089_bib6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anplas.2017.03.012","article-title":"Non-surgical treatments for hidradenitis suppurativa: a systematic review","volume":"62","author":"Robert","year":"2017","journal-title":"Ann Chir Plast Esthet"},{"key":"10.1016\/j.jaad.2019.08.089_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.det.2015.08.013","article-title":"Antibiotic treatment of hidradenitis suppurativa","volume":"34","author":"Bettoli","year":"2016","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2019.08.089_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.12788\/j.sder.2017.021","article-title":"Medical management of hidradenitis suppurativa","volume":"36","author":"Orenstein","year":"2017","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2019.08.089_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clindermatol.2016.10.018","article-title":"Treatments for hidradenitis suppurativa","volume":"35","author":"Andersen","year":"2017","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaad.2016.08.001","article-title":"Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa","volume":"76","author":"Fischer","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib11","article-title":"Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system","volume":"22","author":"Scheinfeld","year":"2016","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2019.08.089_bib12","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijd.14036","article-title":"Ertapenem - a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa","volume":"57","author":"Braunberger","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib13","doi-asserted-by":"crossref","unstructured":"van Straalen KR, Schneider-Burrus S, Prens EP. Current and future treatment of hidradenitis suppurativa [E-pub ahead of print]. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.16768. Accessed October 23, 2019.","DOI":"10.1111\/bjd.16768"},{"key":"10.1016\/j.jaad.2019.08.089_bib14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2016.06.001","article-title":"Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa","volume":"75","author":"Wong","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib15","doi-asserted-by":"crossref","first-page":"8018192","DOI":"10.1155\/2017\/8018192","article-title":"Review of current immunologic therapies for hidradenitis suppurativa","volume":"2017","author":"Shanmugam","year":"2017","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/13543784.2018.1412430","article-title":"Investigational drugs in clinical trials for hidradenitis suppurativa","volume":"27","author":"Theut Riis","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jaad.2019.08.089_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000462979","article-title":"Medical and surgical treatment of hidradenitis suppurativa: a review","volume":"3","author":"Scuderi","year":"2017","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.jaad.2019.08.089_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2340\/00015555-1800","article-title":"The influence of body weight on the prevalence and severity of hidradenitis suppurativa","volume":"94","author":"Kromann","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2019.08.089_bib20","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjd.15233","article-title":"The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide","volume":"177","author":"Jennings","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jdcr.2017.11.024","article-title":"Response to: remission of hidradenitis suppurativa after bariatric surgery","volume":"4","author":"Golbari","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2019.08.089_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjd.15939","article-title":"Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A","volume":"178","author":"Garg","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jamadermatol.2015.4593","article-title":"Factors associated with point-of-care treatment decisions for hidradenitis suppurativa","volume":"152","author":"Garg","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bjd.16261","article-title":"Tobacco smoking and hidradenitis suppurativa: associated disease and an important modifiable risk factor","volume":"178","author":"Micheletti","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/09546634.2017.1395806","article-title":"Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials","volume":"29","author":"Maarouf","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2019.08.089_bib26","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/jdv.15160","article-title":"Anti-TNF\u03b1 therapy modulates mTORC1 signalling in hidradenitis suppurativa","volume":"33","author":"Balato","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.08.089_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.det.2015.08.012","article-title":"Randomized controlled trials for the treatment of hidradenitis suppurativa","volume":"34","author":"van Rappard","year":"2016","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2019.08.089_bib28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2019.08.089_bib29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.08.089_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study","volume":"80","author":"Zouboulis","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib31","unstructured":"Humira [package insert]. North Chicago, IL: AbbVie Inc."},{"key":"10.1016\/j.jaad.2019.08.089_bib32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000484408","article-title":"The magnitude of mTORC1 signalling may predict the response to isotretinoin treatment in patients with hidradenitis suppurativa","volume":"233","author":"De Vita","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2019.08.089_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2008.11.898","article-title":"A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa","volume":"60","author":"Lee","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000343221","article-title":"Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report","volume":"226","author":"van der Zee","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2019.08.089_bib35","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bjd.15769","article-title":"Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2340\/00015555-2794","article-title":"Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab","volume":"98","author":"Schuch","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2019.08.089_bib39","doi-asserted-by":"crossref","unstructured":"Odorici G, Pellacani G, Conti A. Ixekizumab in hidradenitis suppurativa: a case report in a psoriatic patient [E-pub ahead of print]. G Ital Dermatol Venereol. https:\/\/doi.org\/10.23736\/S0392-0488.18.06135-7. Accessed October 23, 2019.","DOI":"10.23736\/S0392-0488.18.06135-7"},{"key":"10.1016\/j.jaad.2019.08.089_bib40","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib46","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib47","first-page":"163","article-title":"Concurrent anticytokine biologics for the management of severe hidradenitis suppurativa: are they safe and effective?","volume":"101","author":"Naik","year":"2018","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2019.08.089_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdcr.2014.09.002","article-title":"Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: a case report","volume":"1","author":"Babalola","year":"2015","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2019.08.089_bib49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jdcr.2017.03.002","article-title":"Combination biologic therapy for the treatment of severe palmoplantar pustulosis","volume":"3","author":"Torre","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2019.08.089_bib50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2133.1986.tb05740.x","article-title":"A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa","volume":"115","author":"Mortimer","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib52","first-page":"44","article-title":"Finasteride in hidradenitis suppurativa: a \u201cmale\u201d therapy for a predominantly \u201cfemale\u201d disease","volume":"9","author":"Khandalavala","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib53","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamadermatol.2013.2874","article-title":"Finasteride for the treatment of hidradenitis suppurativa in children and adolescents","volume":"149","author":"Randhawa","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11154-016-9366-z","article-title":"Hidradenitis suppurativa\/acne inversa: an endocrine skin disorder?","volume":"17","author":"Karagiannidis","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jaad.2019.08.089_bib55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ajd.12362","article-title":"A case series of 20 women with hidradenitis suppurativa treated with spironolactone","volume":"56","author":"Lee","year":"2015","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib56","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000477207","article-title":"A new perspective on isotretinoin treatment of hidradenitis suppurativa: a retrospective chart review of patient outcomes","volume":"233","author":"Huang","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2019.08.089_bib57","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000477615","article-title":"Are there indications for isotretinoin treatment of hidradenitis suppurativa?","volume":"233","author":"Boer","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2019.08.089_bib58","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.08.089_bib59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000443878","article-title":"The ABC of hidradenitis suppurativa: a validated glossary on how to name lesions","volume":"232","author":"Lipsker","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2019.08.089_bib60","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3109\/13880209.2015.1057652","article-title":"Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytes in\u00a0vitro via mTOR-signaling pathway","volume":"54","author":"Liu","year":"2016","journal-title":"Pharm Biol"},{"key":"10.1016\/j.jaad.2019.08.089_bib61","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jdv.14894","article-title":"Insulin resistance in hidradenitis suppurativa: a case-control study","volume":"32","author":"Vilanova","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.08.089_bib62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0253-7613.174388","article-title":"Metformin - for the dermatologist","volume":"48","author":"Bubna","year":"2016","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.jaad.2019.08.089_bib63","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1468-3083.2012.04668.x","article-title":"Metformin for the treatment of hidradenitis suppurativa: a little help along the way","volume":"27","author":"Verdolini","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.08.089_bib64","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bjd.16271","article-title":"Interleukin-36 cytokine family signalling in hidradenitis suppurativa","volume":"178","author":"Emtestam","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib65","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jdermsci.2016.08.010","article-title":"Combination of oral zinc gluconate and topical triclosan: an anti-inflammatory treatment modality for initial hidradenitis suppurativa","volume":"84","author":"Hessam","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2019.08.089_bib66","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/09546634.2016.1273470","article-title":"Effective modified conservative tissue preserving protocol to treat stage I axillary hidradenitis suppurativa: a prospective cohort study of 627 patients with five years follow-up","volume":"28","author":"Shirah","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2019.08.089_bib69","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib71","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.17615","article-title":"Prolonged clindamycin and rifampicin for hidradenitis suppurativa: resist to prevent resistance","volume":"180","author":"Hambly","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.08.089_bib73","first-page":"1","article-title":"Hidradenitis suppurativa: a practical review of possible medical treatments based on over 350 hidradenitis patients","volume":"19","author":"Scheinfeld","year":"2013","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2019.08.089_bib74","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-015-0516-5","article-title":"An update on medical treatment options for hidradenitis suppurativa","volume":"76","author":"Deckers","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2019.08.089_bib75","first-page":"260","article-title":"T helper 17 cell\/regulatory T-cell imbalance in hidradenitis suppurativa\/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities","volume":"179","author":"Melnik","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib77","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2018.06.063","article-title":"Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa","volume":"80","author":"Golbari","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib79","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/bjd.14418","article-title":"Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality","volume":"174","author":"Ingram","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib80","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/ced.12380","article-title":"Hidradenitis suppurativa treated with Clostridium botulinum toxin A","volume":"39","author":"Khoo","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib81","doi-asserted-by":"crossref","first-page":"e226064","DOI":"10.1136\/bcr-2018-226064","article-title":"Successful treatment of stage III hidradenitis suppurativa with botulinum toxin A","volume":"12","author":"Shi","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2019.08.089_bib82","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2133.2007.08069.x","article-title":"Intramuscular immunoglobulin for recalcitrant suppurative diseases of the skin: a retrospective review of 63 cases","volume":"157","author":"Goo","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib83","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s10350-005-0309-0","article-title":"Granulocyte-macrophage colony-stimulating factor for perianal hidradenitis suppurativa: report of a case","volume":"49","author":"Sharon-Guidetti","year":"2006","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.jaad.2019.08.089_bib84","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.12688\/f1000research.11337.1","article-title":"Hidradenitis suppurativa: an update on connecting the tracts","volume":"6","author":"Smith","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.jaad.2019.08.089_bib85","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1203475417746122","article-title":"Surgical treatment of sinus tracts and fistulas in perianal hidradenitis suppurativa","volume":"22","author":"Scholl","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2019.08.089_bib86","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.det.2015.08.007","article-title":"Surgical procedures in hidradenitis suppurativa","volume":"34","author":"Janse","year":"2016","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2019.08.089_bib87","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jdv.14770","article-title":"Hidradenitis suppurativa treated with wide excision and second intention healing: a meaningful local cure rate after 253 procedures","volume":"32","author":"Deckers","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.08.089_bib88","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1468-3083.2011.04203.x","article-title":"Mild to moderate hidradenitis suppurativa treated with local excision and primary closure","volume":"26","author":"van Rappard","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5 suppl 1","key":"10.1016\/j.jaad.2019.08.089_bib89","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jaad.2015.07.044","article-title":"Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis","volume":"73","author":"Mehdizadeh","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib90","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1468-3083.2012.04646.x","article-title":"Secondary intention healing in skin surgery: our own experience and expanded indications in hidradenitis suppurativa, rhinophyma and non-melanoma skin cancers","volume":"27","author":"Bieniek","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.08.089_bib91","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/jdv.12376","article-title":"Skin-tissue-sparing excision with electrosurgical peeling (STEEP): a surgical treatment option for severe hidradenitis suppurativa Hurley stage II\/III","volume":"29","author":"Blok","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.08.089_bib92","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/jdv.12952","article-title":"Surgery under general anaesthesia in severe hidradenitis suppurativa: a study of 363 primary operations in 113 patients","volume":"29","author":"Blok","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.08.089_bib93","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.bjps.2016.05.029","article-title":"A systematic review of the use of lasers for the treatment of hidradenitis suppurativa","volume":"69","author":"John","year":"2016","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.jaad.2019.08.089_bib94","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jaad.2009.07.048","article-title":"Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser","volume":"62","author":"Mahmoud","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib95","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/1744666X.2018.1449647","article-title":"An update on the pathogenesis of hidradenitis suppurativa: implications for therapy","volume":"14","author":"Negus","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaad.2019.08.089_bib96","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/bjd.13385","article-title":"Treatment of hidradenitis suppurativa with intralesional photodynamic therapy using a laser diode attached to an optical cable: a promising new approach","volume":"172","author":"Valladares-Narganes","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib97","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/09546634.2017.1387226","article-title":"Intense pulsed light treatment for patients with hidradenitis suppurativa: beware treatment with resorcinol","volume":"29","author":"Theut Riis","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2019.08.089_bib105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.08.089_bib108","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaad.2017.02.026","article-title":"Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients","volume":"76","author":"Weber","year":"2017","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219328269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219328269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:52:27Z","timestamp":1759272747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219328269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0190962219328269"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.08.089","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.08.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(20)30409-6","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}